PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells

Zheng Bo Hu1, Xiao Hong Liao2, Zun Ying Xu1, Xiao Yang1, Chao Dong1, An Min Jin1 & Hai Lu3

1Department of Orthopedics, Zhu Jiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280, China
2The State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510280, China
3Department of Orthopaedics, The Third Affiliated Hospital of Southern Medical University, Academy of Orthopedics, Guangzhou, Guangdong 510665, China

Abstract

TAp73, a member of the p53 tumor suppressor family, can substitute for p53 function, especially in p53-null and p53-mutant cells. However, TAp73 enrichment and phosphorylation change its transcriptional activity. Previously, we found that the antitumor function of TAp73 was reactivated by dephosphorylation. Polo-like kinase 2 (PLK2) plays an important role in bone development. Using a biological information database and phosphorylation prediction software, we hypothesized that PLK2 phosphorylates TAp73 and inhibits TAp73 function in osteosarcomas. Actually, we determined that PLK2 physically binds to and phosphorylates TAp73 when TAp73 protein abundance is up-regulated by cisplatin. PLK2-phosphorylated TAp73 at residue Ser48 within the TA domain; phosphorylation of TAp73 was abolished by mutating this residue. Moreover, PLK2 inhibition combined with cisplatin treatment in osteosarcoma Saos2 cells up-regulated p21 and puma mRNA expression to a greater extent than cisplatin treatment alone. Inhibiting PLK2 in TAp73-enriched Saos2 cells resulted in inhibited cell proliferation, increased apoptosis, G1 phase arrest, and decreased cell invasion. However, these changes did not occur in TAp73 knockdown Saos2 cells. In conclusion, these findings reveal a novel PLK2 function in the phosphorylation of TAp73, which prevents TAp73 activity in osteosarcoma cells. Thereby, this research provides an insight into the clinical treatment of malignant tumors overexpressing TAp73.

Introduction

Osteosarcoma is the most common bone malignancy. It predominantly affects adolescents and young adults [1], and its treatment remains challenging [2]. The tumor suppressor protein p53 plays a very important role in tumor suppression. In more than half of human cancers, this protein is mutated or deleted through different mechanisms [3, 4]. The TAp73 protein is a member of the p53 family. It has a similar structure to p53 and activates some p53 target genes [5]. TAp73 plays varying roles under different conditions that have yet to be completely elucidated. In contrast with p53, TAp73 is rarely mutated and is frequently overexpressed in human
tumors; [5] further, its functions can at least partially substitute for those of p53.

Since Llamazares et al. [6] first reported the polo-like kinase (PLK) PLK2 in 1991, a total of five members of the PLK family have been reported: [7] PLK1, PLK2, PLK3, PLK4, and PLK5. The PLK family members are involved in the regulation of all cell cycle phases (G1, G2, S, and M). Although studies have shown that PLK1 plays a prosurvival role in human tumors [8, 9], the functions of PLK2 are complex and controversial [10, 11]. In addition, an increasing number of studies have revealed a close interaction between the PLK and p53 families, especially in human cancers. In fact, PLK2 is a unique PLK protein that regulates skeletal development and mitosis [12]. Some reports have suggested that PLK2 functions in osteosarcoma cells; [13–15] however, its associated effects and mechanisms remain to be determined.

The phosphokinase-mediated reversible phosphorylation of proteins helps to coordinate a considerable number of principal cell processes, such as cell growth, proliferation, and apoptosis [16–18]. In our study, we identified several phosphorylation sites on TAp73 using the PhosphoSite database www.phosphosite.org that appear to be associated with distinct functions (Fig. 1A).

To theoretically determine whether PLK2 activates or inactivates TAp73, we used the online bioinformatics phosphorylation predictor Scansite 3.0 [19] (http://scansite3.mit.edu) to predict the phosphorylation sites of TAp73 (Fig. 1B). In addition, we used the predictor GPS-polo 1.0 to identify PLK-binding sites [20] in this protein (Fig. 1C).

We have previously demonstrated that the acidophilic kinase casein kinase 2 (CK2) phosphorylates TAp73 and inhibits its tumor suppressor function [21]. Further, PLK2 recognizes substrates that are similar to CK2 and catalyzes some substrates more efficiently than CK2 [22, 23]. In addition, Songyang et al. [24] have demonstrated that CK2 displays a consensus sequence that is identical to that of the PLK family, which includes PLK2. Thus, we speculated that PLK2 may exert a similar kinase activity and function on Tap73 as CK2.

Finally, integrating the site predictions with the kinase characteristics, DNA states, and face accessibility, we hypothesized that in osteosarcoma, PLK2 phosphorylates Ser48 of TAp73, which acts as a tumor suppressor to...
inhibit TAp73 function (Fig. 1D, details in Supplementary Information).

**Materials and Methods**

**Cell lines**

The human osteosarcoma cell lines Saos2 and MG63 were obtained from the ATCC. Stable TAp73 knockout Saos2 cells (i.e., Saos2 (TAp73-KD)) were generated by transducing Saos2 cells with a pLKO.1-puro lentiviral vector (Addgene) expressing shRNA (targeting the same sequence as siRNA-TAp73), as described previously [25]. Cells were cultured in McCoy’s 5A or DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS). The medium was replaced with fresh medium as necessary, and cultures were maintained at 37°C in the presence of 5% CO₂.

**Transfection**

According to the experiment performed, the appropriate expression vectors (20 μg of Flag-pcDNA3-TAp73, Flag-pcDNA3-TAp73S48A, or Flag-pcDNA3-PLK2 obtained from Dr. Zhi-Min Yuan, Harvard University, USA) and small interfering RNA (200 pmol of siPLK2 or siTAp73, Dharmacon, Lafayette, CO, USA) were transfected into cells using Lipofectamine 2000 transfection reagent (Invitrogen) at 48 h before the experiments were performed, according to the manufacturer’s recommendations and as described previously [26]. Control siRNA (contr-si) and empty pcDNA3 (Invitrogen) were used as controls. As described in our previous study [21], the TAp73 S48A mutant, in which Ser-48 was substituted with Ala (GENEWIZ, Inc., NJ, USA), was confirmed by DNA sequencing.

**Drug treatment**

Cells were seeded at a density of 60–70% at 24 h before the treatments. The DNA damage reagents cisplatin (Qiru Corp., Jinan, China) and adriamycin (ADM, Sigma, St. Louis, MO, USA) were diluted to the indicated concentrations in cell culture medium. The PLK2 inhibitor ELN582646 [27, 28] (Elan Pharmaceuticals, South San Francisco, CA), was diluted to 5 μg/mL in cell culture medium.

**Real-time reverse transcriptase PCR**

Isolated RNA was subjected to reverse transcription and PCR, as described previously [15]. The relative gene expression levels ($2^{-ΔΔCt}$) were normalized to β-actin mRNA, which was used as an internal control. Table 1 shows the primer and siRNA sequences.

| Gene | Primer/Sequence |
|------|----------------|
| Primer | PLK2 Forward, 5’-ATCAACCACCATGCGACTCG-3’ | Reverse, 5’-AAATGGGCGTCTCCTGATG-3’ |
| TAp73 | Forward, 5’-CCATCAGAGGAGGTTACGGA-3’ | Reverse, 5’-TCGGTGTTGGGAGGATGACA-3’ |
| p21 | Forward, 5’-AGCGACCTCCATCCTCACC-3’ | Reverse, 5’-AAGAACAATCTCCACCACCATC-3’ |
| puma | Forward, 5’-TTCCCTCCTGCTGGTCTTCCTA-3’ | Reverse, 5’-ACGGTGCTAGTCTGTCTTCA-3’ |
| β-actin | Forward, 5’-AGTGGGACATCGGCAAG-3’ | Reverse, 5’-GACTCCATATCCTCGTCTTG-3’ |
| siRNA PLK2 | Sequence (549–571): 5’-UCUUUGUAUAUUUCCCUUGGGAAAAGAUUGACAAAGAAA-3’ |
| TAp73 | Sequence (4927–4949): 5’-AUUAAAGUGCUUAAUGCUUAACUGUACCAGUUAAGCAGCUUUAAUGC-3’ |

**Co-immunoprecipitation (co-IP), western blot (WB), and phos-tag WB**

Western blot [21] and co-IP [29] were performed as described previously. Phosphorylated TAp73 was detected by phos-tag WB. Immunocomplexed TAp73 was assessed by conducting a phos-tag MT SDS-PAGE assay (Wako Pure Chemical Industries, Ltd., Japan), as previously described [30]. Additionally, as described previously [21], Flag-PLK2 and Flag-TAp73, or Flag-TAp73 (S48A) was purified using anti-Flag antibodies incubated in kinase buffer overnight, after which the samples were subjected to a TAp73 phos-tag WB. The antibodies used are listed in the Supporting Materials section.

**Metabolic labeling of PLK2 in Saos2 cells**

To determine the half-life of endogenous PLK2, pulse-chase experiments were performed as previously described [31].

**Indirect immunofluorescence microscopy**

Indirect immunofluorescence experiments were performed as described previously [32]. The antibodies used are listed in the Supporting Materials section.

**Flow cytometry (FCM), cell wound-healing assay, and apoptosis assay**

FCM and cell wound-healing assays were conducted as described previously [33, 34]. A terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) kit (Roche, Mannheim, Germany) was used to assess apoptosis according to the manufacturer’s instructions.
Cell counting Kit-8 assay

Cell proliferation was assessed by measuring optical density (OD) using a Cell Counting Kit-8 (Dojindo Laboratories, Kumomato, Japan), according to the manufacturer’s recommendations [35]. The first measurement was performed on day 0, 24 h after cells were seeded in the wells. Absorbance (450 nm) was recorded using a microplate reader (Molecular Devices VMax Kinetic Microplate Reader V Max, Sunnyvale, CA, USA).

Statistical analysis

Each sample was assayed in triplicate. Data are expressed as the mean ± standard deviation (SD). Differences between two groups were compared using the two-tailed Student’s t-test or chi-squared test. Differences between more than two groups were compared using one-way analysis of variance (ANOVA) in conjunction with Dunnett’s post-hoc test, ANOVA for repeated measures or the chi-squared test. Differences were considered significant when $P < 0.05$.

Results

PLK2 physically interacts with TAp73 in vitro and in vivo, and catalyzes TAp73 phosphorylation within TA1 residue S48 in response to cisplatin stimulation

To test our hypothesis, co-IP experiments between endogenous PLK2 and TAp73 were conducted using Saos2 cells stimulated with three different concentrations of cisplatin.
to determine whether PLK2 and TAp73 physically bind to each other. Endogenous PLK2 was found to directly bind to endogenous TAp73 in a cisplatin dose-dependent manner (Fig. 2A). Unexpectedly, negative co-IP results were observed between PLK2 and TAp73, as the abundance of TAp73 was low in Saos2 cells under normal culture conditions.

Because PLK2 is a kinase, we investigated whether it phosphorylates TAp73. Endogenous TAp73 in Saos2 cells was stimulated using cisplatin (50 μg/mL), after which the cells were harvested and subjected to phos-tag WB under different conditions. The phos-tag WB results showed that the intensity of the phosphorylation bands differed depending on the amount of TAp73 protein present and that PLK2 inhibition reduced the amount of phosphorylated TAp73 (Fig. 2B). Because many kinases promote the phosphorylation of this protein, an in vitro phosphorylation assay was performed. Flag-PLK2 and Flag-TAp73 were purified and were then incubated together in kinase buffer for the indicated durations. These samples were then subjected to phos-Tag WB, which revealed that ectopic TAp73 phosphorylation occurred in vitro and increased in a time-dependent manner (Fig. 2C). However, when the purified mutant TAp73 (S48A) was subjected to phos-Tag WB, the phosphorylation signal was nearly absent (Fig. 2D).

PLK2 binding to TAp73 was confirmed in Saos2 cells treated with ADM, and in another human osteosarcoma cell line, MG63, stimulated using cisplatin (Fig. 2A, E).

An effect of PLK2 inhibition on endogenous TAp73 was also confirmed (Fig. 2F).

**PLK2 regulates transcriptional activity of enriched TAp73**

Previous experiments have revealed that PLK2 phosphorylates TAp73 when it is present at a high level. However, whether TAp73 transcription is inactivated remains to be determined. *p21*, a cell cycle inhibitor, and *puma*, a proapoptosis gene, are two of the main target genes of TAp73. The PCR results showed that *p21* and *puma* mRNA expression was increased in response to PLK2 inhibition by siRNA or a PLK2 inhibitor in Saos2 cells treated with cisplatin (Fig. 3A–F). Moreover, the increase in *p21* and *puma* expression was greater in the presence of PLK2 inhibition compared with treatment with cisplatin alone. However, the PLK2-dependent increase in *p21* and *puma* expression did not occur in Saos2 cells that were not treated with cisplatin. In addition, these increases in expression were not observed in cells pretreated with siTAp73 (Fig. 3E–H). Protein expression in these samples was also measured by WB (Fig. 4A, B). These findings suggest that PLK2 regulates TAp73 activity in the presence of TAp73-activating stimuli. However, the mechanism underlying these changes is unclear; therefore, an immunofluorescence confocal microscopy experiment was performed. The results showed that PLK2 inhibited TAp73 translocation to the nucleus (Fig. 5).
TAp73 extends the PLK2 half-life, and PLK2 and TAp73 interact with each other at the posttranslational level

Whether TAp73 directly induces PLK2 transcription remains unknown. Compared with parental cells, PLK2 mRNA expression was not increased when TAp73 was overexpressed or knocked down by siRNA (Fig. 3C) and vice versa (Fig. 3D), indicating that TAp73 did not directly regulate PLK2 gene expression. Moreover, PLK2 expression did not affect TAp73 mRNA expression. Thus, PLK2 and TAp73 do not directly interact with each other at the transcriptional or translational level.

Figure 4. PLK2 and enriched TAp73 affect each other at the protein level. (A) In the presence of cisplatin or Adriamycin, PLK2 did not affect TAp73 protein abundance. (B) In Saos2 cells in the absence of cisplatin, the p21 and puma protein levels did not increase after PLK2 inhibition (P < 0.05). (C) After cisplatin stimulation (50 μg/mL) for the indicated durations, the half-life of the nascent PLK2 protein was approximately 20 min in Saos2 cells, whereas that of the PLK2 protein in Saos2 (TAp73-KO) cells was approximately 15 min.

Figure 5. PLK2 inhibits TAp73 translocation to the nucleus. The upper row shows Saos2 cells treated with cisplatin (50 μg/mL). PLK2 (red) and TAp73 (green) signals are almost uniform in the cytoplasm and are punctuate in the nucleus. The bottom row shows that the TAp73 (green) signal appears more intense within the nucleus when PLK2 is knocked down by siRNA, suggesting that PLK2 inhibits TAp73 translocation to the nucleus.
level. Therefore, we assessed whether TAp73 directly affects PLK2 at the posttranslational level. The co-IP results showed that PLK2 physically bound to TAp73; thus, we analyzed the nascent PLK2 protein by autoradiography, which revealed that its half-life in Saos2 cells was prolonged compared with that in Saos2 (TAp73-KD) cells after cisplatin stimulation (Fig. 4C). Therefore, these findings suggest that PLK2 and TAp73 interact with each other at the posttranslational level.

**PLK2 inhibition blocks cells in G1 phase and increases apoptosis in the presence of enriched TAp73, but not in the presence of a low level of TAp73**

Because PLK2 is associated with the cell cycle G1/S transition and because the combination of PLK2 knockdown and cisplatin treatment in Saos2 cells increases p21 and puma expression, which play roles in cell cycle arrest and apoptosis, we determined the physiological effects of PLK2 manipulation by performing FCM and apoptosis assays to examine the effects of PLK2 inhibition on cells.

An increase in the proportion of cells arrested in the G1 phase was observed (Fig. 6). Furthermore, an apoptotic peak appeared in Saos2 cells treated with cisplatin in the presence or absence of PLK2 inhibition in contrast with untreated cells. Notably, PLK2 inhibition alone reduced the proportion of Saos2 cells in the G1 phase. These results suggest that PLK2 regulates G1 cell cycle progression in a TAp73-dependent manner when TAp73 is enriched, as well as through other mechanisms when this protein is present at a low level.

To further characterize the apoptotic peak observed in cisplatin-treated cells in which PLK2 was inhibited, we performed an apoptotic assay. The results of this analysis

---

**Figure 6.** Enriched TAp73 affects PLK2 by regulating cell cycle G1 progression. Compared with Saos2 cells under normal culture conditions (A, B siRNA control), PLK2 inhibition alone by siRNA (C) or a PLK2 inhibitor (D) decreased the proportion of cells in the G1 phase ($P < 0.05$), which was more evident with siRNA knockdown of PLK2. PLK2 inhibition in the presence of 25 μg/mL cisplatin significantly increased the proportion of cells in the G1 phase (F, G), and this proportion was greater than that with cisplatin stimulation alone ($P < 0.05$). An apoptotic peak appeared with cisplatin treatment (E, F, G).
revealed a significant increase in the proportion of apoptotic Saos2 cells in the presence of cisplatin and PLK2 inhibition compared with cisplatin treatment alone or PLK2 inhibition alone (Fig. 7A). However, the proportion of apoptotic Saos2 (TAp73-KD) cells did not increase when PLK2 was inhibited compared with treatment with cisplatin alone (Fig. 7B). Thus, PLK2 inhibition promoted cisplatin-dependent cell cycle arrest and increased Saos2 cell apoptosis.

**Knockdown of PLK2 inhibits osteosarcoma cell invasive ability and cell proliferation in the presence of enriched TAp73, but the opposite effects occur in the absence of TAp73 enrichment**

Because cell cycle arrest and apoptosis affect cell survival, cell wound-healing and cell proliferation assays were performed. In the cell wound-healing assay, healing occurred in 3 days for Saos2 and Saos2 (TAp73-KD) cells. In contrast, wound healing did not occur by the fifth day (data not shown) in cisplatin-treated Saos2 cells or in PLK2 knockdown Saos2 cells treated with cisplatin, which also exhibited apoptosis (Fig. 8). The results of the proliferation experiments showed that PLK2 inhibition had a suppressive effect on the Saos2 cell growth in the presence of cisplatin, and this finding was not observed in Saos2 (TAp73-KD) cells (Fig. 9). However, PLK2 inhibition alone resulted in an increase in cell proliferation in the absence of cisplatin. Consistent with the results of the FCM assay, these results suggest that PLK2 affects cell fate differently according to TAp73 abundance.

**Discussion**

As a substitute for p53, TAp73 plays an antitumorigenic role under p53-abnormal conditions. However, phosphorylation of TAp73 and variations in TAp73 abundance can result in tumor activity changes. Examination of the phosphorylation kinases of TAp73 is crucial in the assessment of its phosphorylation.

In this study, we have found that the DNA-damaging drug cisplatin stimulates the up-regulation of TAp73 in the osteosarcoma cell line Saos2. Moreover, PLK2 and TAp73 directly interact with each other, and PLK2 phosphorylates TAp73 in vivo and in vitro. Proteins, including TAp73, contain many functional domains [36, 37]. Generally, different protein domains allow for chemical modifications that can subsequently alter the activities and functions of the protein. TAp73 contains the domains [37] TA1, DBD, OD, TA2, and SAM. Previous studies [38–47] have indicated that phosphorylation of the TA1 domain often affects the transcriptional functions of TAp73, inhibiting its antitumor function (Fig. 1A). However, phosphorylation of other domains mainly results in an increase in this function. Thus, identification of the PLK2 phosphorylation site within TAp73 is important for predicting TAp73 function. In this study, in agreement with our predictions, we found that PLK2 phosphorylates Ser48, which is located within the TA1 domain. The PCR and WB results also demonstrated that PLK2 inhibition increased the activity of enriched TAp73. Previous studies [48] have shown that the TAp73 isoform ΔNp73, which lacks the TA domain, has the opposite function of TAp73. This mechanism may be consistent with the inhibitory effect of TA domain phosphorylation in TAp73.

Accumulating evidence strongly suggests a close correlation between PLK2 and TAp73. First, gene knockout experiments have shown that both the PLK2 [12] and TAp73 genes [49–51] play critical roles in embryogenesis and skeletal development, as well as nervous system diseases, but not in tumor development. Second, both genes play significant roles in DNA damage responses in tumor
cells [52–54]. Third, both PLK2 and TAp73 are either up-regulated or down-regulated in tumors depending on the cellular context [55–58]. In this study, we found that PLK2 phosphorylates enriched TAp73, partially suppressing its transcriptional activity in osteosarcoma cells. However, these effects were not observed when TAp73 was present at a low level. TAp73 also stabilized PLK2 by prolonging its half-life, which suggests that TAp73 potentiates PLK2 to regulate cell cycle progression in tumors. Moreover, following up-regulation of endogenous TAp73, PLK2 inhibition resulted in up-regulation of expression of the TAp73 target genes $p21$ and $puma$, inducing G1 phase arrest and apoptosis and impairing cell proliferation. However, cell cycle progression and cell proliferation were promoted when PLK2 inhibition occurred without enrichment of TAp73. These results suggest that PLK2 regulates the cell cycle and cell proliferation through distinct mechanisms in the presence of a low or high TAp73 level.

As mentioned above, whether PLK2 has negative or positive effects in osteosarcoma cells remains unknown. Previous studies have shown that deregulation of PLK2 results in a multinucleated phenotype [59, 60], aberrant cell morphology [31] and aberrant centrioles in U2OS cells [61], all of which are hallmarks of carcinogenesis. Most recently, Jie Li et al. [11] have demonstrated that the PLK2 is essential for the survival of aberrant cells, such as tumor cells. In addition, Matthew et al. have found that the silencing of PLK2 sensitizes tumor cells to the DNA-damaging agents aphidicolin and paclitaxel [62]. In addition, PLK2 activates PLK1 [60], which subsequently abolishes the suppressive activity of p53 in p53 wild-type cells [63, 64]. p53 also directly regulates PLK2 expression as a target gene [65]. Nevertheless, PLK2 promotes the oncogenic effects of mutant p53 in MG63 cells [14]. The above studies demonstrate the tumor-promoting role of PLK2. However, many other studies have indicated that

Figure 8. PLK2 inhibition affects cell invasion via TAp73. (A) Saos2 osteosarcoma cells subjected to PLK2 inhibition alone were completely healed by day 3, similar to the healing rate observed in parental cells. In contrast, stimulation with 15 μg/mL cisplatin with or without PLK2 siRNA knockdown did not result in healing within 3 days. Wounds healed efficiently in TAp73-knockout Saos2 cells (B).
it is a tumor suppressor [66, 67]. In agreement with previous studies, PLK2 inhibition promoted cell cycle progression and cell proliferation in normal culture Saos2 cells, indicating its role as a suppressor. Further, its inhibition resulted in cell cycle arrest and suppression of cell proliferation when TAp73 was enriched by cisplatin, supporting its role as a tumor promoter.

Because TAp73 and PLK2 are involved in DNA damage responses [52–54] and PLK2 inhibition does not cause DNA damage [27], PLK2, a regulator of cell cycle, does not directly affect TAp73 expression in the absence of cisplatin treatment (Figs 3 and 4). In addition, under normal conditions, we found that the TAp73 level was low in Saos2 cells (Fig. 3F). The physiological effects of variations in the PLK2 level on TAp73 may be too weak to be detected. In contrast with our findings, studies have shown that PLK2 is a tumor suppressor that is silenced by hypermethylation in tumor cells [56, 59]. Our research has demonstrated that PLK2 can play a tumor suppressor role through another mechanism that remains unknown. On the other hand, we found that PLK2 plays a role as a tumor promoter in human osteosarcoma cells based on the increased TAp73 observed following treatment with DNA-damaging agents.

Clinically, a large number of malignant tumors that are p53-negative or mutant, such as liver, [68] lung [69], esophageal, [70] rectal, [71] ovarian, [72] bladder, [73] and skin [74] tumors, exhibit wild-type TAp73 overexpression. Therefore, a high TAp73 level is regarded as a poor prognostic marker for cancer patients. Paradoxically, TAp73 gene silencing by methylation has also been reported in a variety of malignant tumors [75, 76] and in bone marrow stromal stem cells [77], suggesting that its low abundance or deficiency may play a role in maintaining undifferentiated cell characteristics. An inverse correlation has been noted between the degree of cell differentiation and the degree of tumor malignancy. As mentioned above, unlike p53, which acts exclusively as a tumor suppressor, TAp73 also plays key roles in cell differentiation and development [55]. Therefore, a low TAp73 level in malignant tumors is reasonable. Conversely, the correlation between a high TAp73 level and poor prognosis may not make intuitive sense; however, this relationship has been confirmed clinically. A possible explanation for this finding is that TAp73 expression in tumors becomes up-regulated under certain conditions, but TAp73 activity remains inhibited. To further clarify this apparent paradox, researchers have used several methods to restore TAp73 function in tumors [69]. In our study, we found that PLK2 inhibition restored enriched TAp73 functions in osteosarcoma cells, which provides insights into this issue.

In conclusion, our study demonstrates a novel mechanism of PLK2 in promoting tumor progression, whereby it directly binds to enriched TAp73, catalyzes Ser48 phosphorylation of TAp73, and inhibits TAp73 transcriptional activity (Fig. 10). PLK2 inhibition may effectively sensitize osteosarcomas to cisplatin treatment through the enrichment of TAp73. Our results may be used to guide anti-tumor treatments in patients whose tumors display TAp73 overexpression.
Acknowledgments

The authors thank the State Key Laboratory of Respiratory Diseases and professor Zhou Rong, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou city, Guangdong, China. Also, we thank the pediatric institute of Dongguan and director Lu Xiaomei, China.

Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Savitskaya, Y. A., G. Rico-Martínez, L. M. Linares-González, E. A. Delgado-Cedillo, R. Tellez-Gastelum, A. B. Alfaro-Rodríguez, et al. 2012. Serum tumor markers in pediatric osteosarcoma: a summary review. Clin. Sarcoma Res. 2:9.
2. Xie, Z. G., Y. Xie, and Q. R. Dong. 2013. Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. Oncol. Lett. 6:1465–1469.
3. Vassilev, L. T. 2005. p53 activation by small molecules: application in oncology. J. Med. Chem. 48:4491–4499.
4. Hainaut, P., and M. Hollstein. 2000. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:81–137.
5. Du, W., P. Jiang, A. Mancuso, A. Stonestrom, M. D. Brewer, A. J. Minn, et al. 2013. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 15:991–1000.
6. Llamazares, S., A. Moreira, A. Tavares, C. Girdham, B. A. Spruce, C. Gonzalez, et al. 1991. Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 5:2153–2165.
7. Zito űni, S., C. Nabaí, S. C. Jana, A. Guerrero, and M. Bettencourt-Dias. 2014. Polo-like kinases: structural variations lead to multiple functions. Nat. Rev. Mol. Cell Biol. 15:435–452.
8. Raab, M., A. Krämer, S. Hehlgans, M. Sanhaji, E. Kurunci-Csacsko, C. Dötsch, et al. 2015. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. Mol. Oncol. 9:140–154.
9. Sanhaji, M., A. Ritter, H. R. Belsham, C. T. Friel, S. Roth, F. Louwen, et al. 2014. Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis. Oncotarget 5:3130–3144.
10. Bowers, S., A. P. Truong, M. Ye, D. L. Aubele, J. M. Sealy, R. J. Neitz, et al. 2013. Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. Bioorg. Med. Chem. Lett. 23:2743–2749.
11. Li, J., W. Ma, P. Y. Wang, P. J. Hurley, F. Bunz, and P. M. Hwang. 2014. Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction. Free Radic. Biol. Med. 73:270–277.
12. Ma, S., J. Charron, and R. L. Erikson. 2003. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol. Cell. Biol. 23:6936–6943.
13. Cizmecioglu, O., A. Krause, R. Bahtz, L. Ehret, N. Malek, and I. Hoffmann. 2012. Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4l). J. Cell Sci. 125:981–992.
14. Shen, T., Y. Li, L. Yang, X. Xu, F. Liang, S. Liang, et al. 2012. Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells. Int. J. Biochem. Cell Biol. 44:423–429.
15. Lin, M., R. Jia, M. Wang, X. Gao, D. Zhu, S. Chen, et al. 2013. The transcription analysis of duck enteritis virus UL49.5 gene using real-time quantitative reverse transcription PCR. Virus Genes 47:298–304.
16. Seet, B. T., I. Dikic, M. M. Zhou, and T. Pawson. 2006. Reading protein modifications with interaction domains. Nat. Rev. Mol. Cell Biol. 7:473–483.
17. Ubersax, J. A., and J. E. Ferrrell. 2007. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 8:530–541.
18. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298:1912–1934.
19. Obenauer, J. C., L. C. Cantley, and M. B. Yaffe. 2003. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31:3635–3641.
20. Liu, Z., J. Ren, J. Cao, J. He, X. Yao, C. Jin, et al. 2013. Systematic analysis of the Plk-mediated phosphorylation in eukaryotes. Brief Bioinform. 14:344–360.
21. Lu, H., C. Yan, X. X. Quan, X. Yang, J. Zhang, Y. Bian, et al. 2014. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer. Neoplasia 16:789–800.
22. Mbefo, M. K., K. E. Paleologou, A. Boucharaba, A. Oueslati, H. Schell, M. Fournier, et al. 2010. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285:2807–2822.
23. Schreurs, S., M. Gerard, R. Derua, E. Waelkens, J. M. Filhol, C. Cochet, et al. 1996. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA,
phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol. Cell. Biol. 16:6486–6493.
25. Chen, D., L. Ming, F. Zou, Y. Peng, B. Van Houten, J. Yu, et al. 2014. TAp73 promotes cell survival upon genotoxic stress by inhibiting p33 activity. Oncotarget 5:8107–8122.
26. Thakur, A., Y. Sun, A. Bollig, J. Wu, H. Biliran, S. Banerjee, et al. 2008. Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin. Cancer Res. 14:4427–4436.
27. Fitzgerald, K., M. Bergeron, C. Willits, S. Bowers, D. L. Aubele, E. Goldbach, et al. 2013. Pharmacological inhibition of Polo Like Kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei. Toxicol. Appl. Pharmacol. 269:1–7.
28. Aubele, D. L., R. K. Hom, M. Adler, R. A. Galemmo, A. P. Truong, et al. 2013. Selective and brain-Permeable Polo-like Kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain. ChemMedChem 8:1295–1313.
29. King, K. E., R. M. Ponnampерuma, C. Allen, H. Lu, P. Duggal, Z. Chen, et al. 2008. The p53 homologue DeltaNp63α interacts with the nuclear factor-κB pathway to modulate epithelial cell growth. Cancer Res. 68:5122–5131.
30. Kinoshita, E., E. Kinoshita-Kikuta, K. Takiyama, and T. Koike. 2006. Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol. Cell Proteomics 5:749–757.
31. Ma, S., M. A. Liu, Y. L. Yuan, and R. L. Erikson. 2003. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB. Mol. Cancer Res. 1:376–384.
32. Goto, H., H. Kosako, K. Tanabe, M. Yanagida, M. Sakurai, M. Amano, et al. 1998. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J. Biol. Chem. 273:11728–11736.
33. Bai, L., L. Ding, S. W. Jiang, H. J. Kang, C. F. Gao, C. Chen, et al. 2014. Down-regulation of FRTα inhibits proliferation and promotes apoptosis of cervical cancer cells in vitro. Asian Pac. J. Cancer Prev. 15:5667–5672.
34. Fu, L., N. Liu, Y. Han, C. Xie, Q. Li, and E. Wang. 2014. ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumour Biol. 35:9263–9268.
35. Zhang, H., W. C. Zhou, X. Li, W. B. Meng, L. Zhang, X. L. Zhu, et al. 2014. 5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wnt/β-catenin signaling pathway. Genet. Mol. Res. 13:5064–5072.
36. Okada, K., S. Kanaya, and K. Asai. 2005. Accurate extraction of functional associations between proteins based on common interaction partners and common domains. Bioinformatics 21:2043–2048.
37. Logotheti, S., A. Pavlopoulou, S. Galtisidis, B. Vojtesek, and V. Zoumpourlis. 2013. Functions, divergence and clinical value of TAp73 isoforms in cancer. Cancer Metastasis Rev. 32:511–534.
38. Burge, S., D. P. Teufel, F. M. Townsley, S. M. Freund, M. Bycroft, and A. R. Fersht. 2009. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation. Proc. Natl Acad. Sci. USA 106:3142–3147.
39. Koida, N., T. Ozaki, H. Yamamoto, S. Ono, T. Koda, K. Ando, et al. 2008. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J. Biol. Chem. 283:8555–8563.
40. Paliwal, P., V. Radha, and G. Swarup. 2007. Regulation of p73 by Hck through kinase-dependent and independent mechanisms. BMC Mol. Biol. 8:45.
41. Gonzalez, S., C. Prives, and C. Cordon-Cardo. 2003. p73alpha regulation by Chk1 in response to DNA damage. Mol. Cell. Biol. 23:8161–8171.
42. Benosman, S., X. Meng, Y. Von Grabowieccki, L. Palamiuc, L. Hricu, I. Gross, et al. 2011. Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. J. Biol. Chem. 286:43013–43025.
43. Merlo, P., M. Fulco, A. Costanzo, R. Mangiacasale, S. Strano, G. Blandino, et al. 2005. A role of p73 in mitotic exit. J. Biol. Chem. 280:30354–30360.
44. Gaiddon, C., M. Lokshin, I. Gross, D. Levasseur, Y. Taya, J. P. Loeffler, et al. 2003. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J. Biol. Chem. 278:27421–27431.
45. Niikura, Y., H. Ogi, K. Kikuchi, and K. Kitagawa. 2010. BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD). Cell Death Differ. 17:1011–1024.
46. Yuan, Z. M., H. Shioya, T. Ishiko, X. Sun, J. Gu, Y. H. Huang, et al. 1999. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814–817.
47. Agami, R., G. Blandino, M. Oren, and Y. Shaul. 1999. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399:809–813.
48. Bunjobpol, W., I. Dulloo, K. Igarashi, N. Concin, K. Matsuo, and K. Sabapathy. 2014. Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death Differ. 21:1240–1249.
Crosstalk between PLK2 and TAp73

49. Pozniak, C. D., S. Radinovic, A. Yang, F. McKeon, D. R. Kaplan, and F. D. Miller. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304–306.

50. Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, et al. 2000. p73-deficient mice have neurological, phenominal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103.

51. Niklashion-Chirou, M. V., J. R. Steinert, M. Agostini, R. A. Knight, D. Dinsdale, A. Cattaneo, et al. 2013. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc. Natl Acad. Sci. USA 110:18952–18957.

52. Shimizu-Yoshida, Y., K. Sugiyama, T. Rogounovitch, A. Ohitsu, H. Namba, V. Saenko, et al. 2001. Radiation-inducible hSNK gene is transcriptionally regulated by p53 binding homology element in human thyroid cells. Biochem. Biophys. Res. Commun. 289:491–498.

53. Levine, A. J., R. Tomasini, F. D. McKeon, T. W. Mak, and G. Melino. 2011. The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol. 12:259–265.

54. Flores, E. R., K. Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, et al. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560–564.

55. Moll, U. M., and N. Slade. 2004. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2:371–386.

56. Syed, N., H. M. Coley, J. Sehouli, D. Koensgen, A. Mustea, P. Slozarek, et al. 2011. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res. 71:3317–3327.

57. Tan, L. B., K. T. Chen, Y. C. Yuan, P. C. Liao, and H. R. Guo. 2010. Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J. Urol. 28:117–122.

58. Syed, N., P. Smith, A. Sullivan, L. C. Spender, M. Dyer, L. Karran, et al. 2006. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107:250–256.

59. Eckerd, F. J. C., A. Kaplan, and K. Streibhardt. 2005. Polo-like kinases and oncogenesis. Oncogene 24:267–276.

60. Matsumoto, T., P. Y. Wang, W. Ma, H. J. Sung, S. Matoba, and P. M. Hwang. 2009. Polo-like kinases mediate cell survival in mitochondrial dysfunction. Proc. Natl Acad. Sci. USA 106:14542–14546.

61. Cizmecioglu, O., S. Warnke, M. Arnold, S. Duensing, and I. Hoffmann. 2008. Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7:3548–3555.

62. Matthew, E. M., T. J. Yen, D. T. Dicker, J. F. Dorsey, W. Yang, A. Navaraj, et al. 2007. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 6:2571–2578.

63. Liu, X., and R. L. Erikson. 2003. Polo-like kinase (Plk1) depletion induces apoptosis in cancer cells. Proc. Natl Acad. Sci. USA 100:5789–5794.

64. Burns, T. F., P. Fei, K. A. Scata, D. T. Dicker, and W. S. El-Deiry. 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol. Cell. Biol. 23:5556–5571.

65. Matthew, E. M., L. S. Hart, A. Austrinidis, A. Navaraj, N. G. Dolloff, D. T. Dicker, et al. 2009. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 8:4168–4175.

66. Liu, L. Y., W. Wang, L. Y. Zhao, B. Guo, J. Yang, X. G. Zhao, et al. 2014. Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells. Mol. Med. Rep. 11:3033–3038.

67. Buhlmann, S., T. Racek, A. Schwarz, S. Schaefer, and B. M. Putzer. 2008. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. J. Mol. Biol. 378:20–30.

68. Zhao, W., B. Zhang, X. Guo, X. Zhang, J. Hu, X. Hu, et al. 2014. Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma. Cancer Biomark. 14:197–202.

69. Moll, U. M., 2003. The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res., 9: 5501–5507, 2003, and P. Puig et al., p73 Expression in carcinomas of the bladder. Clin. Cancer Res., 9:5642-5651, 2003. Clin. Cancer Res. 9:5437–5441.

70. Chen, Y., X. Wang, F. Li, L. Zhang, L. Ma, and Y. Liu. 2015. Relationship between expression of P27, Fragile Histidine Triad (FHT), phosphatase and tensin homolog deleted on chromosome ten (PTEN), p73, and prognosis in esophageal squamous cell carcinoma. Ann. Diagn. Pathol. 19:33–36.

71. Toumi, A. A., A. El Hadj Oel, L. K. Ben Mahmoud, M. Ben Hmida Ael, I. Chaar, L. Gharbi, et al. 2010. The prognostic value of p73 overexpression in colorectal carcinoma: a clinicopathologic, immunohistochemical, and statistical study of 204 patients. Appl. Immunohistochem. Mol. Morphol. 18:128–136.
72. Hofstetter, G., A. Berger, M. Chamson, E. Müller-Holzner, D. Reimer, H. Ulmer, et al. 2011. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature. Int. J. Gynecol. Pathol. 30:527–531.
73. Stravopodis, D. J., P. K. Karkoulis, E. G. Konstantakou, S. Melachroinou, A. D. Lampidonis, D. Anastasiou, et al. 2009. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int. J. Oncol. 34:137–160.
74. Ganzetti, G., C. Rubini, A. Campanati, A. Zizzi, E. Molinelli, L. Rosa, et al. 2015. IL-17, IL-23, and p73 expression in cutaneous melanoma: a pilot study. Melanoma Res. 25:232–238.
75. Zhao, Y., C. Fei, X. Zhang, Y. Zhang, J. Guo, S. Gu, et al. 2013. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis. Tumour Biol. 34:165–172.
76. Zekri, A. R., A. A. Bahnasy, F. E. Shoeab, W. S. Mohamed, D. H. El-Dahshan, F. T. Ali, et al. 2014. Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J. Adv. Res. 5:27–40.
77. Liang, W., C. Lu, J. Li, J. Q. Yin, and R. C. Zhao. 2010. p73alpha regulates the sensitivity of bone marrow mesenchymal stem cells to DNA damage agents. Toxicology 270:49–56.

**Supporting Information**

Additional supporting information may be found in the online version of this article:

Data S1. The process of prediction and hypothesis formation.
Data S2. Antibodies described in the article.
Data S3. Editorial certificate.